Radiometals for Diagnostic Imaging and Theranostics

radiopharmaceutical used in diagnostic imaging and theranostics

The first radiometal molybdenum-99/technetium-99m generator was developed at the Brookhaven National Laboratory in 1959, subsequently, in 1964, technetium-99m radiotracers were being established at the Argonne National Laboratory.  Currently, 85% of radiopharmaceuticals use technetium-99m based imaging agents.  These imaging agents can be used to evaluate organ function, detect cancer, measure blood flow and follow metabolic processes. Continue reading